AzTrials
AzTrials

Spinal Cord InjuryNCT04955509

A Scar Recognition Software for Chronic Spinal Cord Injury (SCI)

An observational study of Spinal Cord Injury, run by Peking University Third Hospital.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

To construct and validate a software to recognize scar for patients with chronic SCI based on multimodal MRI. Read more about this study

Who is it for?
Any age
Conditions the study is for
Spinal Cord Injury
What is being tested?
MRI
How many people
25 participants
Where
No sites listed yet
Study dates
1 Sep 2021to 1 Jun 2023
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Child, Adult, Older adult

Study population: The patients came from the Peking University Third Hospital.

Who may be able to join

  • (Prospective part) compliance to MRI scan
  • (Prospective part) no MRI contraindication
  • (Retrospective part) available conventional MRI data
  • clinical diagnosis of SCI (the course of disease≥1 year)

Who cannot join

  • prior head or neck surgery or accompanying diseases with neurologic deficits and/or symptoms including multiple sclerosis, motor neuron disease, or spinal cord tumor
  • images with motion artifact

Trial locations and contacts

No sites are listed yet.

Ouyang Hanqiang contact

ouyanghanqiang@bjmu.edu.cn

About this study

Official title: In Vivo Optimization and Clinical Application of a Scar Recognition Software for Chronic Spinal Cord Injury (SCI)

To construct and validate a software to recognize scar for patients with chronic SCI based on multimodal MRI.

Read the detailed description

Spinal cord injury (SCI) is a kind of serious neurologic damage caused by violence to the spinal cord, resulting in various functions of the body below the injury level, including motor, sensory, sphincter, and reflex dysfunction in varying degrees, usually resulting in permanent and irreversible functional loss or paralysis of patients. The treatment of SCI is an essential problem in the world. In the past decades, experimental research on SCI involves genes, proteins, cells, and tissues, and has made great progress. However, these studies mainly focus on the SCI at the early stage, rather than the later stage. The reason is that in the later stage, scar formed by glial cells and fibroblasts in the injured area is a physical and chemical barrier, which inhibits the regeneration and myelination of nerve axons and results in inhibiting spinal cord repairment. Therefore, before the treatment of chronic SCI, the key problem is to distinguish glial scar tissue from normal tissue and eliminate its influence.

As glial scar inhibits axon regeneration, eliminating glial scar is necessary for the repair of the injured spinal cord. In recent years, a large number of experimental studies have been carried out to destroy the process of glial scar formation after SCI by enzyme digestion and antibody. Though these methods reduced glial scar, residual glial scars were reported in animal experiments. Compared to biochemical methods, surgical resection of glial scar tissue is a relatively simple and effective method to eliminate glial scars. Due to the limited regeneration ability of nerves after SCI, it is important to identify scar tissue accurately before operations to avoid surgical injury to normal tissue, which is also the premise of further research and clinical application of various interventional treatment methods.

Magnetic resonance imaging (MRI) is one of the most commonly used non-invasive imaging techniques to evaluate the degree of injury and therapeutic effect of SCI. Nemours MRI studies on SCI show the impact of SCI on the central nervous system from the structural and functional level and prove the potential application value of MRI in assisting doctors in the diagnosis of SCI. A small number of previous studies have used magnetization transfer imaging, and diffusion tensor imaging to detect glial scar tissue, showing the potential application value of these images in differentiation between glial scar and surrounding normal spinal cord. However, because glial cells, which constitute glial scar, are also important components of normal spinal cord tissue, previous studies only identified glial scar from a single aspect, such as tissue type, macromolecular component, or water molecular diffusion strength. Therefore, their specificities were unsatisfactory. Relative methods were unable to identify glial scar accurately and finally resulted in difficulty in treatment arrangement and evaluation of prognosis, which hinders the development of SCI treatment research.

Combing multimodal MRI, including conventional MRI and diffusion MRI, with supervised machine learning makes accurate glial identification in chronic SCI possible. multimodal MRI can depict the differences between scar tissue and non-scar tissue from the aspects of cell composition, water molecular dispersion, structural complexity, etc. Comparing to MRI with a single model, multimodal MRI provides more specific features. Machine learning, a way to construct robust and accurate models, can mine the quantitative relationship between imaging features and clinical diagnosis results, reveal MRI feature markers of the glial scar, to improve the accuracy of identification. The research work, combined with medicine, imaging, and artificial intelligence technology, is expected to solve the problem of accurate and non-invasive identification of glial scar in chronic SCI, which has potential application value for laboratory research and clinical treatment of chronic SCI.

Being tested
MRI
Medical subject headings
Spinal Cord Injuries

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MRIOther

    conventional MRI and diffusion MRI

Study groups in NCT04955509
Study groupRoleWhat they receive
Trainingrandom splitting based on random sequences generated by engineers to train and optimize a machine learning model
Receives: Other: MRI
Testingrandom splitting based on random sequences generated by engineers to evaluate the performance of the model
Receives: Other: MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Performance of the fitted model

    positive predictive value (PPV)

    Measured: through study completion, an average of 2 year

  2. Performance of the fitted model

    sensitivity (SE)

    Measured: through study completion, an average of 2 year

  3. Performance of the fitted model

    Dice coefficient score (DSC)

    Measured: through study completion, an average of 2 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted8 Jul 2021
  2. Study start1 Sep 2021 (estimated)
  3. Primary completion1 Dec 2022 (estimated)
  4. Study completion1 Jun 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
25 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04955509
Sponsor's protocol ID
M2020400,M2020356
Status last verified
Sep 2020
First submitted
29 Jun 2021
Last updated
8 Jul 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Spinal Cord Injury, run by Peking University Third Hospital.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 8 Jul 2021. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Mengze Zhang (18600393607, zmzforever@pku.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Performance of the fitted model (time frame: through study completion, an average of 2 year). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2021.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
Clinical Trial NCT04955509 | AzTrials